BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16470538)

  • 1. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma.
    Lagonigro MS; Tamborini E; Negri T; Staurengo S; Dagrada GP; Miselli F; Gabanti E; Greco A; Casali PG; Carbone A; Pierotti MA; Pilotti S
    J Pathol; 2006 Apr; 208(5):615-23. PubMed ID: 16470538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors.
    Bozzi F; Tamborini E; Negri T; Pastore E; Ferrari A; Luksch R; Casanova M; Pierotti MA; Bellani FF; Pilotti S
    Cancer; 2007 Apr; 109(8):1638-45. PubMed ID: 17342771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
    Tamborini E; Miselli F; Negri T; Lagonigro MS; Staurengo S; Dagrada GP; Stacchiotti S; Pastore E; Gronchi A; Perrone F; Carbone A; Pierotti MA; Casali PG; Pilotti S
    Clin Cancer Res; 2006 Dec; 12(23):6920-8. PubMed ID: 17145809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas.
    Tamborini E; Casieri P; Miselli F; Orsenigo M; Negri T; Piacenza C; Stacchiotti S; Gronchi A; Pastorino U; Pierotti MA; Pilotti S
    J Pathol; 2007 Jun; 212(2):227-35. PubMed ID: 17471466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
    Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
    Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy.
    Wehler TC; Frerichs K; Graf C; Drescher D; Schimanski K; Biesterfeld S; Berger MR; Kanzler S; Junginger T; Galle PR; Moehler M; Gockel I; Schimanski CC
    Oncol Rep; 2008 Mar; 19(3):697-704. PubMed ID: 18288404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations.
    Liegl B; Gülly C; Reich O; Nogales FF; Beham A; Regauer S
    Histopathology; 2007 Mar; 50(4):448-52. PubMed ID: 17448020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors.
    Welin S; Fjällskog ML; Saras J; Eriksson B; Janson ET
    Neuroendocrinology; 2006; 84(1):42-8. PubMed ID: 17047316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
    Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?
    Liegl B; Leithner A; Bauernhofer T; Windhager R; Guelly C; Regauer S; Beham A
    Histopathology; 2006 Dec; 49(6):576-81. PubMed ID: 17163842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
    Orzan F; Terreni MR; Longoni M; Boari N; Mortini P; Doglioni C; Riva P
    Oncol Rep; 2007 Jul; 18(1):249-52. PubMed ID: 17549375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
    Perrone F; Jocollè G; Pennati M; Deraco M; Baratti D; Brich S; Orsenigo M; Tarantino E; De Marco C; Bertan C; Cabras A; Bertulli R; Pierotti MA; Zaffaroni N; Pilotti S
    Eur J Cancer; 2010 Oct; 46(15):2837-48. PubMed ID: 20692828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
    Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma.
    Shimada A; Hirato J; Kuroiwa M; Kikuchi A; Hanada R; Wakai K; Hayashi Y
    Pediatr Blood Cancer; 2008 Feb; 50(2):213-7. PubMed ID: 17941064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
    Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
    J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
    Negri T; Bozzi F; Conca E; Brich S; Gronchi A; Bertulli R; Fumagalli E; Pierotti MA; Tamborini E; Pilotti S
    J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade.
    Rozeman LB; Hameetman L; van Wezel T; Taminiau AH; Cleton-Jansen AM; Hogendoorn PC; Bovée JV
    J Pathol; 2005 Sep; 207(1):61-71. PubMed ID: 16007578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer.
    Gockel I; Moehler M; Frerichs K; Drescher D; Trinh TT; Duenschede F; Borschitz T; Schimanski K; Biesterfeld S; Herzer K; Galle PR; Lang H; Junginger T; Schimanski CC
    Oncol Rep; 2008 Oct; 20(4):845-50. PubMed ID: 18813825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.
    Fjällskog ML; Lejonklou MH; Oberg KE; Eriksson BK; Janson ET
    Clin Cancer Res; 2003 Apr; 9(4):1469-73. PubMed ID: 12684421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.